cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.22059209
title: Supplementary Material for: Long-term safety, clinical and immunological outcomes in Primary Membranous Nephropathy with Severe Renal Impairment treated with cyclophosphamide and steroid-based regimen

description: Introduction and Aims Therapy of Primary Membranous nephropathy (PMN) with progressive advanced kidney dysfunction is challenging with limited literature and no clear therapeutic strategies. This is due to the scant evidence of effectiveness and uncertainty around the risk-benefit profile of immunosuppression (ImS) when eGFR is less than 30 ml/min. We aimed to determine long term clinical outcomes in patients with PMN and severe renal impairment treated with combined cyclophosphamide and steroids. Methods The study is a single-centre retrospective longitudinal cohort study. All patients (between 2004-2019) with biopsy confirmed PMN who initiated combination therapy with steroids and cyclophosphamide and had an eGFR of ≤30ml/min/1.73m2 at the time of initiation of therapy were included for analysis. Clinical and laboratory parameters including Anti-PLA2R-Ab were monitored as per standard clinical guidance. Primary outcome was achievement of partial remission. Secondary outcomes included immunological remission, need for renal replacement therapy, and adverse effects. Results Eighteen patients with median age of 68 (IQR 58-73) years and 5:1 M:F ratio received the combination therapy when eGFR was ≤30ml/min/1.73m2 (CKD-EPI). At time of immunosuppression, median eGFR and uPCR were 23 (IQR 18-27) ml/min/1.73m2 and 1000 (IQR 838-1285) mg/mmol respectively. Median follow-up was for 67 (IQR 27-80) months. 16 patients (89%) achieved partial Remission and 7 (39%) achieved complete remission. eGFR increased by 7ml/min/1.73m2 (27%) after one year of starting immunosuppression treatment and 12ml/min/1.73m2 at end of follow-up. Two patients (11%) developed end stage renal disease needing renal replacement therapy. 67% achieved both immunological and clinical remission. Two (11%) patients required hospitalization secondary to infections, 4 (22%) patients developed cancer and 4 patients died (22%). Conclusion Combination therapy with cyclophosphamide and steroids is effective in achieving partial remission and improving renal function in PMN with advanced renal dysfunction. Prospective controlled studies are required to provide further evidence and improve outcomes in such patients.
DOI: 10.6084/m9.figshare.21101686
title: Effect of probiotics for regulation of inflammatory response in radiation-induced enteritis

description: <strong>Effect of probiotics for regulation of inflammatory response in radiation-induced enteritis</strong>
DOI: 10.6084/m9.figshare.21101686.v2
title: Effect of probiotics for regulation of inflammatory response in radiation-induced enteritis

description: <strong>Effect of probiotics for regulation of inflammatory response in radiation-induced enteritis</strong>
DOI: 10.6084/m9.figshare.22059212
title: Supplementary Material for: Long-term safety, clinical and immunological outcomes in Primary Membranous Nephropathy with Severe Renal Impairment treated with cyclophosphamide and steroid-based regimen

description: Introduction and Aims Therapy of Primary Membranous nephropathy (PMN) with progressive advanced kidney dysfunction is challenging with limited literature and no clear therapeutic strategies. This is due to the scant evidence of effectiveness and uncertainty around the risk-benefit profile of immunosuppression (ImS) when eGFR is less than 30 ml/min. We aimed to determine long term clinical outcomes in patients with PMN and severe renal impairment treated with combined cyclophosphamide and steroids. Methods The study is a single-centre retrospective longitudinal cohort study. All patients (between 2004-2019) with biopsy confirmed PMN who initiated combination therapy with steroids and cyclophosphamide and had an eGFR of ≤30ml/min/1.73m2 at the time of initiation of therapy were included for analysis. Clinical and laboratory parameters including Anti-PLA2R-Ab were monitored as per standard clinical guidance. Primary outcome was achievement of partial remission. Secondary outcomes included immunological remission, need for renal replacement therapy, and adverse effects. Results Eighteen patients with median age of 68 (IQR 58-73) years and 5:1 M:F ratio received the combination therapy when eGFR was ≤30ml/min/1.73m2 (CKD-EPI). At time of immunosuppression, median eGFR and uPCR were 23 (IQR 18-27) ml/min/1.73m2 and 1000 (IQR 838-1285) mg/mmol respectively. Median follow-up was for 67 (IQR 27-80) months. 16 patients (89%) achieved partial Remission and 7 (39%) achieved complete remission. eGFR increased by 7ml/min/1.73m2 (27%) after one year of starting immunosuppression treatment and 12ml/min/1.73m2 at end of follow-up. Two patients (11%) developed end stage renal disease needing renal replacement therapy. 67% achieved both immunological and clinical remission. Two (11%) patients required hospitalization secondary to infections, 4 (22%) patients developed cancer and 4 patients died (22%). Conclusion Combination therapy with cyclophosphamide and steroids is effective in achieving partial remission and improving renal function in PMN with advanced renal dysfunction. Prospective controlled studies are required to provide further evidence and improve outcomes in such patients.
DOI: 10.6084/m9.figshare.22059212.v1
title: Supplementary Material for: Long-term safety, clinical and immunological outcomes in Primary Membranous Nephropathy with Severe Renal Impairment treated with cyclophosphamide and steroid-based regimen

description: Introduction and Aims Therapy of Primary Membranous nephropathy (PMN) with progressive advanced kidney dysfunction is challenging with limited literature and no clear therapeutic strategies. This is due to the scant evidence of effectiveness and uncertainty around the risk-benefit profile of immunosuppression (ImS) when eGFR is less than 30 ml/min. We aimed to determine long term clinical outcomes in patients with PMN and severe renal impairment treated with combined cyclophosphamide and steroids. Methods The study is a single-centre retrospective longitudinal cohort study. All patients (between 2004-2019) with biopsy confirmed PMN who initiated combination therapy with steroids and cyclophosphamide and had an eGFR of ≤30ml/min/1.73m2 at the time of initiation of therapy were included for analysis. Clinical and laboratory parameters including Anti-PLA2R-Ab were monitored as per standard clinical guidance. Primary outcome was achievement of partial remission. Secondary outcomes included immunological remission, need for renal replacement therapy, and adverse effects. Results Eighteen patients with median age of 68 (IQR 58-73) years and 5:1 M:F ratio received the combination therapy when eGFR was ≤30ml/min/1.73m2 (CKD-EPI). At time of immunosuppression, median eGFR and uPCR were 23 (IQR 18-27) ml/min/1.73m2 and 1000 (IQR 838-1285) mg/mmol respectively. Median follow-up was for 67 (IQR 27-80) months. 16 patients (89%) achieved partial Remission and 7 (39%) achieved complete remission. eGFR increased by 7ml/min/1.73m2 (27%) after one year of starting immunosuppression treatment and 12ml/min/1.73m2 at end of follow-up. Two patients (11%) developed end stage renal disease needing renal replacement therapy. 67% achieved both immunological and clinical remission. Two (11%) patients required hospitalization secondary to infections, 4 (22%) patients developed cancer and 4 patients died (22%). Conclusion Combination therapy with cyclophosphamide and steroids is effective in achieving partial remission and improving renal function in PMN with advanced renal dysfunction. Prospective controlled studies are required to provide further evidence and improve outcomes in such patients.
DOI: 10.6084/m9.figshare.22059068
title: rawdata

description: Genotype-phenotype data
DOI: 10.6084/m9.figshare.22059068.v1
title: rawdata

description: Genotype-phenotype data
DOI: 10.5517/ccdc.csd.cc2bxz8j
title: CCDC 2172798: Experimental Crystal Structure Determination

description: Related Article: Dhruva Bhat, L Spoorthy, R Sharanya, M Siddesh, Mahesha, A.H Udaya Kumar, N.K. Lokanath|2023|J.Mol.Struct.|1280|135054|doi:10.1016/j.molstruc.2023.135054
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2ddnp5
title: CCDC 2216707: Experimental Crystal Structure Determination

description: Related Article: Quinton J. Bruch, Noah D. McMillion, Chun-Hsing Chen, Alexander J. M. Miller|2023|Inorg.Chem.|62|2389|doi:10.1021/acs.inorgchem.2c04188
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.6084/m9.figshare.22059236
title: Supplementary Material for: Long-term safety, clinical and immunological outcomes in Primary Membranous Nephropathy with Severe Renal Impairment treated with cyclophosphamide and steroid-based regimen

description: Introduction and Aims Therapy of Primary Membranous nephropathy (PMN) with progressive advanced kidney dysfunction is challenging with limited literature and no clear therapeutic strategies. This is due to the scant evidence of effectiveness and uncertainty around the risk-benefit profile of immunosuppression (ImS) when eGFR is less than 30 ml/min. We aimed to determine long term clinical outcomes in patients with PMN and severe renal impairment treated with combined cyclophosphamide and steroids. Methods The study is a single-centre retrospective longitudinal cohort study. All patients (between 2004-2019) with biopsy confirmed PMN who initiated combination therapy with steroids and cyclophosphamide and had an eGFR of ≤30ml/min/1.73m2 at the time of initiation of therapy were included for analysis. Clinical and laboratory parameters including Anti-PLA2R-Ab were monitored as per standard clinical guidance. Primary outcome was achievement of partial remission. Secondary outcomes included immunological remission, need for renal replacement therapy, and adverse effects. Results Eighteen patients with median age of 68 (IQR 58-73) years and 5:1 M:F ratio received the combination therapy when eGFR was ≤30ml/min/1.73m2 (CKD-EPI). At time of immunosuppression, median eGFR and uPCR were 23 (IQR 18-27) ml/min/1.73m2 and 1000 (IQR 838-1285) mg/mmol respectively. Median follow-up was for 67 (IQR 27-80) months. 16 patients (89%) achieved partial Remission and 7 (39%) achieved complete remission. eGFR increased by 7ml/min/1.73m2 (27%) after one year of starting immunosuppression treatment and 12ml/min/1.73m2 at end of follow-up. Two patients (11%) developed end stage renal disease needing renal replacement therapy. 67% achieved both immunological and clinical remission. Two (11%) patients required hospitalization secondary to infections, 4 (22%) patients developed cancer and 4 patients died (22%). Conclusion Combination therapy with cyclophosphamide and steroids is effective in achieving partial remission and improving renal function in PMN with advanced renal dysfunction. Prospective controlled studies are required to provide further evidence and improve outcomes in such patients.
DOI: 10.6084/m9.figshare.22059236.v1
title: Supplementary Material for: Long-term safety, clinical and immunological outcomes in Primary Membranous Nephropathy with Severe Renal Impairment treated with cyclophosphamide and steroid-based regimen

description: Introduction and Aims Therapy of Primary Membranous nephropathy (PMN) with progressive advanced kidney dysfunction is challenging with limited literature and no clear therapeutic strategies. This is due to the scant evidence of effectiveness and uncertainty around the risk-benefit profile of immunosuppression (ImS) when eGFR is less than 30 ml/min. We aimed to determine long term clinical outcomes in patients with PMN and severe renal impairment treated with combined cyclophosphamide and steroids. Methods The study is a single-centre retrospective longitudinal cohort study. All patients (between 2004-2019) with biopsy confirmed PMN who initiated combination therapy with steroids and cyclophosphamide and had an eGFR of ≤30ml/min/1.73m2 at the time of initiation of therapy were included for analysis. Clinical and laboratory parameters including Anti-PLA2R-Ab were monitored as per standard clinical guidance. Primary outcome was achievement of partial remission. Secondary outcomes included immunological remission, need for renal replacement therapy, and adverse effects. Results Eighteen patients with median age of 68 (IQR 58-73) years and 5:1 M:F ratio received the combination therapy when eGFR was ≤30ml/min/1.73m2 (CKD-EPI). At time of immunosuppression, median eGFR and uPCR were 23 (IQR 18-27) ml/min/1.73m2 and 1000 (IQR 838-1285) mg/mmol respectively. Median follow-up was for 67 (IQR 27-80) months. 16 patients (89%) achieved partial Remission and 7 (39%) achieved complete remission. eGFR increased by 7ml/min/1.73m2 (27%) after one year of starting immunosuppression treatment and 12ml/min/1.73m2 at end of follow-up. Two patients (11%) developed end stage renal disease needing renal replacement therapy. 67% achieved both immunological and clinical remission. Two (11%) patients required hospitalization secondary to infections, 4 (22%) patients developed cancer and 4 patients died (22%). Conclusion Combination therapy with cyclophosphamide and steroids is effective in achieving partial remission and improving renal function in PMN with advanced renal dysfunction. Prospective controlled studies are required to provide further evidence and improve outcomes in such patients.
DOI: 10.5281/zenodo.7624551
title: VARIABLE SELECTION FOR CLASSIFICATION AND FORECASTING OF THE FAMILY FIRM'S SOCIOEMOTIONAL WEALTH

description: Dataset of the paper entitled "Variable selection for classification and forecasting of the family firm's socioemotional wealth"
DOI: 10.5281/zenodo.7624550
title: VARIABLE SELECTION FOR CLASSIFICATION AND FORECASTING OF THE FAMILY FIRM'S SOCIOEMOTIONAL WEALTH

description: Dataset of the paper entitled "Variable selection for classification and forecasting of the family firm's socioemotional wealth"
DOI: 10.6084/m9.figshare.21972797
title: raw data.rar

description: The potential targets and pathways of PFHF in the treatment of endometriosis were predicted by network pharmacology. The effect of PFHF on the proliferation, apoptosis and cell cycle, migration and invasion of HEcESCs was detected by CCK-8 method, flow cytometry and Transwell chamber experiment. Label-free quantitative proteomics based on mass spectrometry was used to analyze the protein mass spectrum of differential expression of HEcESCs before and after PFHF, and the biological information was analyzed. The effects of PFHF on the mRNA and protein expression of pathway related genes predicted in HEcESCs were detected by reverse transcription quantitative polymerase chain reaction and Western bloting.
DOI: 10.6084/m9.figshare.21972797.v1
title: raw data.rar

description: The potential targets and pathways of PFHF in the treatment of endometriosis were predicted by network pharmacology. The effect of PFHF on the proliferation, apoptosis and cell cycle, migration and invasion of HEcESCs was detected by CCK-8 method, flow cytometry and Transwell chamber experiment. Label-free quantitative proteomics based on mass spectrometry was used to analyze the protein mass spectrum of differential expression of HEcESCs before and after PFHF, and the biological information was analyzed. The effects of PFHF on the mRNA and protein expression of pathway related genes predicted in HEcESCs were detected by reverse transcription quantitative polymerase chain reaction and Western bloting.
DOI: 10.6084/m9.figshare.22059254
title: Impact of Fully Guided Implant Planning Software Training on The Knowledge Acquisition of Dental Undergraduate Students in Implant Planning

description: Impact of Fully Guided Implant Planning Software Training on The Knowledge Acquisition of Dental Undergraduate Students in Implant Planning
DOI: 10.6084/m9.figshare.22059254.v1
title: Impact of Fully Guided Implant Planning Software Training on The Knowledge Acquisition of Dental Undergraduate Students in Implant Planning

description: Impact of Fully Guided Implant Planning Software Training on The Knowledge Acquisition of Dental Undergraduate Students in Implant Planning
DOI: 10.6084/m9.figshare.156395.v64
title: 2nd year Drosophila Developmental Genetics practical

description: This is the teaching material for the <em>Drosophila</em> module of the Developmental Genetics RSM (research skills module) held at the Faculty of Biology, Medicine and Health of The University of Manchester each year. This practical course runs over 6 days and is organised and supervised by Andreas Prokop. This module has been taught and optimised over a few years. Emphasis is on: <em>1) Drosophila</em> as a model system in research 2) the use of fly genetics (transgenic approaches and mutations) in combination with histological techniques to study mechanisms of development 3) transferable skills including how to design figures and their legends, how to compose laboratory protocols and how to file data securely This module also shows how practical work can be intercalated with exercises on applied fly genetics training, thus filling gaps in experimental protocols with useful activities, enriching the learning outcome and enhancing the fundamental understanding of <em>Drosophila</em> as a model organism. To make this genetics training accredited even on large courses, a novel hybrid e-assessment strategy has been developed, and we regularly apply it on our courses (50-65 students). This e-assessment and its principal strategies have been published in the G3 journal and a test exam is available online (3rd link below). Please, submit any comments in the comment box below or contact me directly: Andreas.Prokop@manchester. ac.uk Note, that a Powerpoint presentation "Roote+Prokop-SupplMat-3.ppt" is required on this module. It can be accessed from the second link below. It is also directly linked out from the two manuals in this resource.
DOI: 10.6084/m9.figshare.22059269
title: Supplementary Material for: Long-term safety, clinical and immunological outcomes in Primary Membranous Nephropathy with Severe Renal Impairment treated with cyclophosphamide and steroid-based regimen

description: Introduction and Aims Therapy of Primary Membranous nephropathy (PMN) with progressive advanced kidney dysfunction is challenging with limited literature and no clear therapeutic strategies. This is due to the scant evidence of effectiveness and uncertainty around the risk-benefit profile of immunosuppression (ImS) when eGFR is less than 30 ml/min. We aimed to determine long term clinical outcomes in patients with PMN and severe renal impairment treated with combined cyclophosphamide and steroids. Methods The study is a single-centre retrospective longitudinal cohort study. All patients (between 2004-2019) with biopsy confirmed PMN who initiated combination therapy with steroids and cyclophosphamide and had an eGFR of ≤30ml/min/1.73m2 at the time of initiation of therapy were included for analysis. Clinical and laboratory parameters including Anti-PLA2R-Ab were monitored as per standard clinical guidance. Primary outcome was achievement of partial remission. Secondary outcomes included immunological remission, need for renal replacement therapy, and adverse effects. Results Eighteen patients with median age of 68 (IQR 58-73) years and 5:1 M:F ratio received the combination therapy when eGFR was ≤30ml/min/1.73m2 (CKD-EPI). At time of immunosuppression, median eGFR and uPCR were 23 (IQR 18-27) ml/min/1.73m2 and 1000 (IQR 838-1285) mg/mmol respectively. Median follow-up was for 67 (IQR 27-80) months. 16 patients (89%) achieved partial Remission and 7 (39%) achieved complete remission. eGFR increased by 7ml/min/1.73m2 (27%) after one year of starting immunosuppression treatment and 12ml/min/1.73m2 at end of follow-up. Two patients (11%) developed end stage renal disease needing renal replacement therapy. 67% achieved both immunological and clinical remission. Two (11%) patients required hospitalization secondary to infections, 4 (22%) patients developed cancer and 4 patients died (22%). Conclusion Combination therapy with cyclophosphamide and steroids is effective in achieving partial remission and improving renal function in PMN with advanced renal dysfunction. Prospective controlled studies are required to provide further evidence and improve outcomes in such patients.
DOI: 10.6084/m9.figshare.22059269.v1
title: Supplementary Material for: Long-term safety, clinical and immunological outcomes in Primary Membranous Nephropathy with Severe Renal Impairment treated with cyclophosphamide and steroid-based regimen

description: Introduction and Aims Therapy of Primary Membranous nephropathy (PMN) with progressive advanced kidney dysfunction is challenging with limited literature and no clear therapeutic strategies. This is due to the scant evidence of effectiveness and uncertainty around the risk-benefit profile of immunosuppression (ImS) when eGFR is less than 30 ml/min. We aimed to determine long term clinical outcomes in patients with PMN and severe renal impairment treated with combined cyclophosphamide and steroids. Methods The study is a single-centre retrospective longitudinal cohort study. All patients (between 2004-2019) with biopsy confirmed PMN who initiated combination therapy with steroids and cyclophosphamide and had an eGFR of ≤30ml/min/1.73m2 at the time of initiation of therapy were included for analysis. Clinical and laboratory parameters including Anti-PLA2R-Ab were monitored as per standard clinical guidance. Primary outcome was achievement of partial remission. Secondary outcomes included immunological remission, need for renal replacement therapy, and adverse effects. Results Eighteen patients with median age of 68 (IQR 58-73) years and 5:1 M:F ratio received the combination therapy when eGFR was ≤30ml/min/1.73m2 (CKD-EPI). At time of immunosuppression, median eGFR and uPCR were 23 (IQR 18-27) ml/min/1.73m2 and 1000 (IQR 838-1285) mg/mmol respectively. Median follow-up was for 67 (IQR 27-80) months. 16 patients (89%) achieved partial Remission and 7 (39%) achieved complete remission. eGFR increased by 7ml/min/1.73m2 (27%) after one year of starting immunosuppression treatment and 12ml/min/1.73m2 at end of follow-up. Two patients (11%) developed end stage renal disease needing renal replacement therapy. 67% achieved both immunological and clinical remission. Two (11%) patients required hospitalization secondary to infections, 4 (22%) patients developed cancer and 4 patients died (22%). Conclusion Combination therapy with cyclophosphamide and steroids is effective in achieving partial remission and improving renal function in PMN with advanced renal dysfunction. Prospective controlled studies are required to provide further evidence and improve outcomes in such patients.